Welcome to the Analyst Presentations for the 2nd Quarter and the 1st Half of 2023, Bumrungrad Hospital Public Company Limited. I am Achariya Sanrattana, Investor Relations and Sustainability. Today, as usual, we will begin the presentations with some of the things that I would like to mention about our 2nd quarter performance. Then we will have our management here to talk about the key takeaways in the 2nd quarter by Khun Neil Sorrentino, our Corporate Chief Strategy Officer. Then followed by the financial performance by Khun Oraphan Buamuang, our Chief Financial Officer. Then we will have the business update by our Chief Executive Officer, Khun Artirat Charukitpipat. Without further ado, I would like to start the presentations with the first slide here. On this slide here, it shows the revenue from the hospital operations in all segments. That is the Thai, the expat, and the international, comparing year-over-year to the 2019 or the pre-COVID-19 level. You can see here that the performance in terms of the revenue, the performance actually better than recovering performance from the COVID-19 already. In terms of the revenue of the Thai segment and the expat segment, already exceeded since the third quarter back in 2020, and it continued to grow. This is a proven that during the pandemic period, we took it as an opportunity for us to be more resilient about our strategy. During the pandemic period, we did a lot of promotional offers to our patients that are living in Thailand, as the, our international business still got impact from the travel restrictions around the world. Also, we did a lot of online marketing to attract the new patients coming to Bumrungrad, and also to retain our existing patients as well. In addition, we are moving towards the digitalizations of Bumrungrad. We created our own Bumrungrad Application by our own in-house technology team, and we have been receiving a positive feedback from it. Like, for example, the numbers of users has been increasing over the years. Also, if you look in terms of the revenue from the international business, it's already exceeded the pre-COVID-19 level since the second quarter of last year, in line with easing of the travel restrictions in several countries around the world. In the second quarter of this year, the international business actually already exceeded by 35% compared to the second quarter of 2019. Here on the next slide, I would like to zoom in into our Middle East business trend. On this graph, you can see that the revenue from the Middle East are actually already grew beyond the pre-COVID-19 level since the second half of last year, uplifted by the strong revenue intensity due to the higher complexity of care of our Middle East patients. During the COVID-19 period, we will be able to maintain a strong relationship with our Middle East business. That is the Qatar, Kuwait, and the UAE remains our top international revenue contributor. Going forward for the Middle East market, we see a positive trend going forward, as we will continue to build up our existing market and also expand to the new market where we see the opportunity. Also, definitely, we're going to continue to provide excellent patient experience. Like, for example, in the second half, we recently add the Arabic language into our Bumrungrad Application. Now on the next slide here, I would like to mention about our China market. On the trend here for the China market, we can see that we saw a recovery trend for the Chinese market already since the COVID-19 subsided in the last year. Also, after China reopened their border in the beginning of this year, we still expect to see a recovering numbers of Chinese tourists coming back to Thailand, as Thailand has long been the top destination for Chinese tourists. Also going forward, with our Women's Center that we just launched, the fertility center and the IVF clinic, we expect that we can attract the Chinese patients come to Bumrungrad, as the Women's Center has been a top service for our Chinese patients. I would like to mention about our cost management. Since the beginning of this year, in the first half, we did continue the cost management program to drive the margin gain. On the graph here, it shows the percentage of the cost of hospital to the operating revenue. You can see that it has been falling from the last, from the end of last year and also from the years earlier. The inflationary impact mitigations continue to be successful, despite the cost-push inflation that has been an ongoing issue over the years. For example, the higher electricity price. We expect the economy of scale to be further and the manpower management and operational efficiency, efficiency to accumulate, and we remain committed to the prudent use of the OT and the headcount. I will go quickly over the discount rate in the second quarter. In this second quarter, the discount rate was at 11.4%. It's a slightly increased Q over Q from 11.1%. This is due to, in the second quarter, we did the annual health fair event to lessen the impact of the low seasonality in the second quarter. It has, so it's increased a little bit. We expect further tapering of other program, and also the discount rate is expected to continue to fall, but in a balancing manner. On this last page here, I would like to update about our sustainability. We finalized our solar panel installations project on rooftop of the Building A already, under the power purchase agreement or the PPA. The capacity for this project is going to be 131 kW peak, and we will receive the discount electricity price from the power that's generated from the solar. This is the starting point for moving towards the sustainability by using more of the renewable energy. Also I would like to mention that in the second quarter, we were happy to receive to be included in the ESG100 that was ranked by the Thaipat Institute, where they look at both the financial performance and also the ESG performance of the company. Also, we have been a constituent of the FTSE4Good continuously since 2019. Also for the MSCI, we maintain our A label for this year, and also we still a constituent of the EPISC. Now that's it for my part of presentations. Now, I would like to hand over the presentations to Khun Neil Sorrentino, to talk about the key takes away in the second quarter. Welcome to Q2 Bumrungrad Hospital Public Company Limited Analyst Presentation for the Year 2023. We are, we are indeed gratified and very proud of the performance of the company, on behalf of management to the benefit our shareholders. Very proud of what, what the organization has been able to achieve, not only for quarter 2, 2023, but actually 1H 2023. The performance has been an 11-year high. I'm gonna show early, in a little bit, I'm going to show what that performance differential has been. Our high for, for the last 10, 11 years has been 2018, although we continue to show 2019. I'm gonna display a little bit of information about 2018, which was our high point over the last 10, 11 years, but I'll get to that in a moment. The, the takeaways for the quarter were significantly driven in terms of performance drive of EBITDA and NOPAT growth on the international side. Even though we had Ramadan and we had Songkran in Q2, the international business beyond the Middle Eastern business, which was still quite strong in the quarter, is what really drove the overall performance. With that international business comes more sick patients, and with that becomes greater resource consumption and greater revenue intensity. And that's, that's really was the story for the quarter, but it was, it was, it was a decade long high in terms of its strength for the organization. We're, as I said, we're, we're really quite gratified about that. When I go through the volume growth for each one of the market segments, you will also see the numbers showing that the volume growth for international, including contribution by Middle East, even though during Ramadan, was very strong for the quarter, and it translated into record earnings, record EBITDA, record NOPAT, and record margin change growth upward that we have not had really since the beginning of the company became a public company in 1989. The other significant driver for the quarter, while not as high as Middle East or high as the balance of international, when you look at our China revenue growth, that, that was fairly dramatic for us, up, up about 20% from the quarter, from quarter one to quarter two, and the total number was about THB 157 million, of which THB 101 million of that THB 157 million was true international revenue from patients coming from China into the country. I expect that revenue growth to continue throughout the balance of 2023. As China continuous to open up, there's more and more non-commercial private Chinese nationals coming to Thailand. On cost control, you heard Khun Om talk about percentage of costs relative to revenue, and that's always a relevant, it's always a relevant metric. When you look deeper into that number, what it shows is, is that full-time equivalents and overtime were, were significantly controlled quarter to quarter, and it made a contribution, a significant contribution, to that to that ratio of revenue versus overall cost, and it coming down somewhere around 50%. In addition, at our, at our shareholder board meeting on Wednesday evening, our shareholder board of directors approved the interim dividend for the shareholders of record. By the way, the payout for this, for this dividend payout will be September 10th. It was a record payout. The EPS for 1H 2022, which, I'll remind you, was a 10-year high, was THB 2.38. In 1H 2023, the EPS, basic EPS, was THB 4.19. The board on Wednesday evening agreed to pay on an interim dividend THB 1.35 DPS, dividend per share, which was an all-time record for the company. I'll talk later about guidance for Q3. Let me get into the detail for you for the quarter beyond what Khun Om talked about. Next slide. For Q2, the top-line revenue growth was 24.1%. I take you back to my guidance for Q1. I said double-digit revenue growth. For Q1, it was 47%. I guided double-digit revenue growth for Q2, I will remind you that I did say to you that that would be less, principally because of Songkran and Ramadan. Honestly, I didn't expect it to be 24%. It was a, it was an outstanding quarter for us, and you can see the 1H, the 1Q growth, 2022 versus 2023, it was almost 47% change. Very, very dramatic. I will remind you that 2022 was our strongest year in 10 years, and 2023, at least through 1H, is far exceeding that. Next slide. As we look at the pieces of the business for, for the quarter and for 1H, international, of course, led the way, stronger yet than a year ago. In 2Q 2022, it rose by 4% to 53 from 49. You can see the other distribution of growth, 12% for expat, and Thai business was 35%. When you look deeper into these numbers, you'll see that, especially Thai and expat, the revenue intensity for the quarter, while the numbers are close on a percentage of revenue basis, the revenue intensity per quarter was strong throughout all of these three segments in the market. Typically, it's always the case for international business and specifically the Middle Eastern business. In the quarter, we had very, very sick people coming to the hospital in all three phases of the market segment. Of course, you can see from 1H 2022 to 1H 2023, similar numbers, but stronger numbers overall in 2023. The revenue intensity wasn't as strong in 2022 as it was in 2023. Next slide. As you do a comparative of the, of the market segments on net patient revenue, you can see overall that from Q2 2022 to Q2 2023, it was up 23% for international, for overall. For international, it was up almost 33%. That was the big driver for, for the quarter, year-over-year. For Thai business, it was up 13%, and for expat, it was up almost 13%, 12.9%. In each one of the segments, we didn't have any negative variances period-over-period, not only for the quarter, but also for the year through 1H, for both 1H 2023 and 1H 2022. Next slide. When you look at Middle East and China, the Middle East business from a year ago to this quarter, 2Q 2023, was up 84.3% for the quarter. Indochina was down 5.2%. The story there for Indochina was, well, there was two elements to that story. First one was Bangladesh. If you go back a year ago, we had extraordinary pent-up demand that came through from Bangladesh. We also had a lot of fly-in, very sick patients from Bangladesh, and we didn't keep up with that pent-up demand driving into the institution in Q2 2023 because it was such a huge number in Q2 2022. That's the reason for the variance. The other aspect of this - 5.2 was Myanmar. In Q2 2023, you couldn't get passport stamped, you couldn't get visas stamped because of the political unrest in the country. That affected travel from Myanmar to Thailand. That has now abated. In Q3, we're seeing the business coming back to normal standards from Myanmar. That's the reason for the - 5.2. Next slide. Still, go back to that previous slide. Still, if you look at the variation in 1H 2023 to 1H 2022, the business was still up 19.3% and 111% on Middle East. Very strong comparative growth year-over-year. Next slide. Here is the, the top 10 nationalities for, for the quarter and for 1H period-over-period. You can see what the numbers say for themselves, but at the bottom, you'll see that international was up almost 33% for the quarter, quarter-over-year ago, and for the year was up almost 62%, led by the top five countries: Qatar, Myanmar, Kuwait, Cambodia, and UAE. You have to look at these percentages relative to their revenue, not only relative to the 10% or 58%. What does it mean from a revenue contribution standpoint? If you look at Myanmar, it could be 300-400 million Thai baht in revenue. The percentage may look small, but the revenue base is pretty substantial still from a market like Myanmar. It's number two in our market segment. If you look at number seven, that's also of interest for the quarter. Quarter-over-quarter a year ago, the business was up 56.3%. We had a dramatic drive of expat, as well as international U.S. travel patients coming into the institution. It was a combination, very strong combination of those two pieces, driving the revenue up 56%, for both expat and international U.S. travelers coming to Thailand, for the quarter. Very strong performance for U.S. in the in Q2 2023. Next slide. Now we get to the, the, the bottom line performance for, for the company. What, what did it all translate into? I've done something a little different for you this time that I haven't done in the past, and that show you a comparative of the quarters by year. If you look to the left, you will see that I've shown you the typical Q2 2023 versus Q2 2022. The EBITDA and the EBITDA margins. Firstly, let's take the margins. The margins jumped year-over-year for the quarter, almost 5% to 38.9%. That was the highest EBITDA margin in the company's history, Q2 2023. In Q2 2022, that EBITDA margin was 34%. If I take you back farther to our, our highest year in the decade, in the decade, the EBITDA margin was 34.7%. We exceeded that by almost 4%, well over 4%. More importantly, when you look at the EBITDA contribution, for the quarter, it was THB 2 billion 394 million, and in Q2 2018, it was THB 1 billion 486. Quite a change in the performance of the company. The contextual performance of the company from an international business standpoint contribution has been incredibly dramatic since 2018. If we go on the other side to 1H, as opposed to comparison of the quarters, you can also look at the first half of the year for 2023, almost THB 4.6 billion in EBITDA for 1H. You can see the comparatives. I won't read them to you. You can see them for yourself. The comparatives for 1H 2022, 1H 2019, and 1H 2018, 2018 being the high watermark. Before 1H 2023, that high watermark was THB 3.126 billion. We far, far exceeded that in 1H 2023 by a dramatic amount. Let's go now to the NOPAT summary. These are very, very similar relationships that I've shown you for EBITDA, but I won't read you the numbers to the bottom of it, exactly what the NOPAT numbers were, dramatically higher, than what we've been doing from a historical standpoint. But it's the margins that I want to draw your attention to. The NOPAT margin in 2023 was 28.4%. From the prior year, it was up almost 5%, almost 5% greater. That's a function of the type of business we're driving into the organization, and it's a function of good cost control, and it's a function of the resource consumption, what I call revenue intensity, of the type of patients that we bring into this institution. It's all of those elements combined that create this kind of a thing. It's not a linear relationship. I've talked to the investor community about this point, and it's an important one. It's not about the volume, it's about the quality and the type of the volume that we source from around the world. For 1H 2023 on NOPAT last year, 1H was THB 1.891 billion. For 2022, 1H. For 1H 2023 was THB 3.331 billion. An incredibly large% change, 1H over 1H, 2022 versus 2023. Next slide, please. Another piece of our business that has also had an astounding quarter, and for that matter, an astounding 1H. I'm not gonna read you these numbers except to, to remark about the EBITDA margin and the net profit margin. 42.6% EBITDA margin for the quarter, 33.5 net profit margin, which is higher than what's going on in the medical center. The 1H numbers, they're even higher, 1H 2020 through 2022 over 2023. We have, and I'll talk about this in a little bit, but we, we've just completed a brand-new reconformance and renovation of our VitalLife building. We'll be having a grand opening on September 20th. We had moved out of the building. We, we gutted it, completely redid it. It's, it's spectacular-looking, and we'll be moving into it on September 20th next month. Next slide. I wanna talk a little bit now about the expansion roadmap for, for the company. Most significant to that expansion roadmap is our greenfield project, led by David Boucher in Phuket. That project is coming along since we last spoke to you. The land has been purchased for almost, I think, THB 300 million, THB 297 million, THB 300 million. We have engaged the architect. The architect will be DWP. We have engaged already the environmental impact study consultancy. That process is ongoing. We're hopeful that we can get the EIA consultancy approvals done in the next, hopefully 10 months, and from that point on, we'll start moving dirt, building foundations, and getting to that point where we can actually see concrete coming out of the ground. We'll continue to keep you updated about that. David has a whole host of plans that he's that he's putting in motion as we speak. He will be moving to Phuket from Bangkok in September. He's in the process of amassing a small but focused team and trying to continue to develop this greenfield. For our next analyst presentation in November, David will be making a presentation about the status update of the Phuket project. Let's take 2023 first. We have finished the Soi One project, phase I, which is a car park of 200 spaces. Since we last spoke to you, we have agreed to now continue phase II and phase III, which are two buildings, additional on that plot. We are going to add 59 additional beds in the middle building, and on the third building to the right of the middle building will be an Advanced Diagnostic Center, and we will have our own oncology, Bumrungrad Oncology Institute, in that, in that third building. It's gonna be very, very exciting. The new VitalLife building, which I talked to you about a little bit ago, will be opening, as I said, September 20th. We, in 2023, completed the expansion of an additional nine beds for ICU 3. In talking about ICU 3, in November of this year, we will be moving our lab to another location outside the hospital, and inside the hospital, we'll be adding a brand-new ICU 5, which will be 12 new ICU beds. We'll start that in November, and we'll finish it in midyear 2024. While that's going on, in September, we will also start the construction, what we call an annex building. Those of you who know our campus know that there's Soi One/ 1, and as you go down that small little soi, there's the loading dock on the left. We own a piece of property on the, on the left, soi. The loading dock's on the right. We're gonna build a building there, which will be a Women's and Children's Outpatient Center. We'll also build and have approved by BMA, a walkway across the street, directly into the hospital, so that physicians and patients and family can walk from the building over the top of the street, right into the hospital. That's called an annex, annex building for now. We'll change the name once it's finished, but annex means annexing into, into the hospital. It'll be a women's and children's center, outpatient women's and children's center. Moving to 2025, I mentioned the Phuket project, which continues. We put it in 2025, because our expectation is somewhere in Q2, Q3, that'll open in 2025. David is gonna open 150 beds. We'll finish 150 beds. He'll open 50 beds at a time, as needed, along with the Advanced Diagnostic Center. It will open in advance of the actual inpatient beds. Phase two will be an additional 100 beds whenever we need them. They'll be shelled in, but all the mechanical, electrical, and plumbing will already be in there. As I said, on the Soi One project, we're gonna add 59 additional licensed beds to complement our 580 beds here for future expansion, so we have full capacity. As it turns out, our Q3 has just begun, and we don't really have a lot of raw data in hand because it just began July 1. As you look at July, and as you look at the beginning of August, the quarter has started out very robust for, for the company. We'll see where it ends at the end of Q3, but it looks like that as time goes on here, these 59 beds will be, will be used and will be needed, and will be used in the years ahead. Next slide. I wanted to show you this because this is, this is something that since COVID ended, we've been able to reach out into the world and look at, and study, and analyze our referral offices all over the world. When COVID was in play, we had about 55 to 60 Bumrungrad referral offices around the world. Some of those were... Many of those were virtual, some of those were real, meaning owned, bricks and mortar by us. Our latest two are in Saudi Arabia. Since COVID passed, thankfully, that number from 50 to 60, depending upon the, the day of the month, has now moved up to 83 referral offices, and this is the context of those, of those named type referral offices. We have 52 of them that are non-Middle East referral offices. International Middle Eastern offices, we have 15, local non-Middle East referral offices, three, and local Middle East referral offices, 13. I show you this because this is a principle, not sole, but a principle driver of our international business all over the world. We're going to take this mapping, 'cause we know how to do this over the years. We're gonna take this mapping approach and penetration approach in different market types, next slide, and look at where will we be in 2024 and 2025? We are an international medical tourism destination provider of care. Commonwealth of Independent States, you may know the list of these 10 countries. We have an intention over the next two years to make headway into these markets. We do see some patients from these markets, mainly because of medical tourism, arrivals from these markets into Bangkok. We plan on penetrating some of these markets in certain, some different ways than the way we do other markets. I'll get into that, as the quarters go by, but this is where. There are other markets, but this is where some of our future growth will come from, from these CIS, CIS countries. We're right now beginning our 2024 budgeting process for the company, and we start next week, as a matter of fact, and that'll go on through our board meeting in November, and we'll finalize that process then. Some of these markets will be in those business plans in 2024, but I expect some of them will also be in the business plans for 2025. Take me back, please, to the takeaways, if you would. Slide. The one item that I didn't cover for you was the Q3 top-line revenue growth guidance. I, I am continue to gu- I'm continuing to guide double-digit revenue growth, but I expect to see revenue growth somewhere between what we did in Q1 and Q2. Q1 was about 47% growth off of Q4. Very, very strong. Q2 was surprisingly strong at 23%-24%. I would expect the revenue growth, double, double-digit revenue growth, will be somewhere between those two numbers. It's, it's, it's a guess, obviously, but it's an educated guess based upon our track record through 1H and the unofficial raw data that we see through a month and a half of Q3. What that will be in the end is anyone's guess. Things can always happen up and down, but we expect Q3 I expect Q3 to be a good quarter for us. What that translates into, we'll see and report back to you at our next analyst presentation meeting. I thank you for your attention. Please join us for our webcast, our live webcast next week. I think, it's going to be on Thursday. Is that correct? Wednesday. August 16th, at 10:00 A.M., Bangkok time. You're most welcome to join. We'll answer any and all questions you may have. Thank you again for your attention, and I'll close here. Thank you. Sawasdee kha. Good morning, everyone. I'm Oraphan Buamuang, Chief Financial Officer. I'm pleased to report you all the financial highlight and financial performance of second quarter and first half 2023. Financial highlight. In second quarter and first half 2023, financial performance, total revenue, EBITDA, and net profit amount were improved when compared to the same period last year, and also above year 2019 peak with situation, as shown in the first table. The improvement mainly came from the higher contribution of international segment had a positive impact to patient volume and revenue intensity continuously in this year. In term of profit margin, in second quarter 2023, EBITDA margin and net profit margin were 38.9% and 28.4% respectively, which are the new high record. I will walk you through more detail in the next section. Financial performance. The consolidated revenue in second quarter this year was THB 6,147 million, increased from second quarter 2022 by 24.1%, and also above than second quarter 2019 by 42.7%. The revenue improvement in second quarter this year came from the increased in revenue from non-Thai patient by 28.6% and Thai patient by 13.7% when compared to second quarter last year. For first half 2023, the consolidated revenue was THB 12,235 million, increased from first half last year by 34.4%, and also above than first half 2019 by 35.8%. In term of revenue contribution by nationality, the contribution of international in second quarter this year increased to 65% from 62% in second quarter last year, mostly due to an increased revenue from non-Thai patient by 28.6%, which more than revenue from Thai patient increased at 13.7%. For first half 2023, revenue contribution from international, international patient also raised to 66%, which is close to 68% in first half 2019. The contribution was coming back to year 2019 peak with situation. In term of revenue contribution by service, in 2Q 2023, revenue contribution from inpatient service increased to 52% from 46% in the same period last year, due to IPD revenue increased at 36.8%, which more than OPD revenue increased at 7.5%. This mostly due to higher volume and intensity of IPD case. In 1H 2023, revenue contribution from inpatient service also increased to 51% from 47% in the same period last year, with the same reason already mentioned. In term of revenue contribution by payer type, the government third party contribution in 1H this year increased to 18% from 11% in 1H last year, mostly due to revenue of government sponsor increased by 127%. This associated with Middle East revenue increase. Insurance contribution in first half this year slightly increased to 18% from 17% in the same period last year, due to insurance revenue in first half this year increased year-over-year by 38%. Self-pay contribution in first half this year declined to 63% from 71% in first half 2022, mostly due to revenue from self-pay increased at 19%, which lower than revenue growth rate of government third party payer and insurance payer. In term of EBITDA and EBITDA margin, as a result of increased revenue and continued cost management program, EBITDA in second quarter 2023 was THB 2,394 million, improved from same period last year by 40% and improved from second quarter 2019 by 105%, with EBITDA margin 38.9%, which is the new high record. EBITDA in first half 2023 was THB 4,594 million, improved from same period last year by 60% and improved from first half 2019 by 65%, with EBITDA margin 37.5%. In terms of net profit and net profit margin, net profit of second quarter 2023 was THB 1,748 million, which improved by 50% and 141% from second quarter 2022 and second quarter 2019 respectively. Net profit margin of second quarter this year improved to 28.4% from 23.5% and 16.8% in second quarter 2022 and second quarter 2019 respectively. First half 2023, net profit was THB 3,331 million, which improved by seventy-... 6% and 84% from first half 2022, and first half 2019 respectively. Net profit margin of first half this year improved to 27.2% from 20.8% and 20.1% in first half 2022, and first half 2019 respectively. In term of leverage ratio, net debt to EBITDA of first half this year was negative at 0.4x due to less net debt, and net debt to equity in first half 2023 was also negative at 0.2 x due to less net debt as well. This is our financial highlight and financial performance of second quarter and first half 2023. Thank you for your attention. Today, I would like to present about hospital operation updates in Q2 2023. Let's start with Bumrungrad core competency. I would like to emphasize again about 4C1W, which are critical care, complicated, cutting-edge technologies, collaboration of expertise, and wellness. We continuously strive to find the better ways to deliver the best care possible to our patients. In Q1 this year, we already promoted our heart institute and neuro critical care services. For the second quarter, we have promoted a new service focused on limb preservation, foot, and nail care. It is a significant step toward expanding and offerings a specific healthcare needs on various foot and nail related issues for wound care and diabetes patients. This service, we got a very good feedback from Arabic patients. In the next one, this is our Eye Excellence Center. We promote our Eye Excellence Center, because we have four subspecialties of our ophthalmologists. We did the press conference on May 31st. In June, it has a significant impact that the whole revenue of our Eye Excellence Center improved around 5%, and especially the key products improved around 25% and 10% respectively. The next one is our fertility center and IVF center. For IVF clinic, we have opened IVF clinic. We have the numbers of physicians that they can deliver the very high success rate. We did the open house in Q1 to emphasize our service, about we have the holistic service for the fertility and IVF patients. We continue our marketing activities by promoting IVF content in domestic markets via online channel and TikTok, and arrange the webinar for international market. The result from the promote and open house, we got the nearly 30% year-on-year of the number of IVF patients. The next one is the Genomic Medicine Institute. We very proud to present this service, because Bumrungrad is the pioneer to promote genomic medicine services, because we have our own geneticist in-house, and we strongly focus in genomic medicine in the various programs, such as whole genome sequencing, whole exome sequencing, and genetic cancer, for cancer and for heart disease. We use every channel, including online channels, and got very good response from our customers. We also sign MOU with Dar Al- Shifa Hospital in Kuwait to endorse our Genomic Medicine Institute, and we have very good feedback from the Kuwait market, and they plan to send numbers of the genetic test patients to Bumrungrad Hospital as well. We also joined the ACMG conference and present how genomic medicine is an innovative approach that allies with the advancement of personalized healthcare. The performance of preventive genomic clinic grow up significantly by achieve in terms of volume, 27% year-on-year, and revenue increase around 37% year-on-year, and many more to come. We just promoted our Chief Scientific Officer, Dr. Polakit, to be the leader of this, this Genomic Medicine Institute. The next one, as you know, that we continuously to develop and enhance our Bumrungrad Application. Lately, we just launched Bumrungrad Application in Arabic version, and we also implement Internet of Medical Things, or IoMT, and can connect various health device, such as Fitbit, Google Fit, Oura Ring, to gather the patient generate health data. The doctors can see the patient data in the dashboard and can monitor our patients' health data via Bumrungrad application, and it show up on our doctor's mobile phone. This is very innovative and move forward thinking approach of the patient care. This is to show you award, and I think everyone knows about Newsweek, that this is the third consecutive years of Bumrungrad Hospital to be one of 250 world best hospital, and we are the only one hospital in Thailand that achieved this award. We also have various award that show in the slide, and lately, we also got the Thailand’s Best Managed Companies from Deloitte as well. This is we would like to recognize our hospital's management, our practice, and our dedication to excellence and outstanding performance. That's all for me for Q2. Now we come to the end of the presentations. Thank you very much everyone for listening in. Please be reminded that we will have the live Q&A sessions on August 16th at 10:00 A.M., for those of you who got invited. In the meantime, if you have any questions, please feel free to send your questions to ir@bumrungrad.com. Before that, we will see you again in the next quarter. Thank you very much again.